{"filing":{"accession_number":"0001104659-26-106312","cik":"0001850119","ticker":"IPSC","company_name":"Century Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"tm2625030d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926106312/tm2625030d1_8k.htm"},"events":[{"id":32340,"run_id":29713,"accession_number":"0001104659-26-106312","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Century Therapeutics appointed Joseph Truitt as a director and member of the Compensation Committee, effective September 9, 2026. The Board expanded from six to seven directors to accommodate the appointment. Truitt brings significant biotechnology leadership experience as CEO of iECURE and Chairman of Larimar Therapeutics, and will receive an initial option grant of 148,000 shares and a $40,000 annual retainer.","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35494,"accession_number":"0001104659-26-106312","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Joseph Truitt as a director and member of the Compensation Committee, effective September 9, 2026. The Board increased its size from six to seven directors specifically to accommodate this appointment. While the disclosure includes compensatory details (initial option grant of 148,000 shares and $40,000 annual retainer), the principal disclosed action is Truitt's appointment to the Board, making this an exec_appointment event. The appointment is material as it affects board composition and governance at a publicly traded biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:14:46.287361+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35495,"accession_number":"0001104659-26-106312","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Joseph Truitt to Century Therapeutics' Board of Directors, announced via press release on September 9, 2026. Truitt brings significant biotechnology leadership experience as CEO of iECURE and Chairman of Larimar Therapeutics, with prior executive roles at BioSpecifics and Achillion. This is a material governance event affecting the composition of the board during a critical period when the company is advancing two key programs toward regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:14:46.287361+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35494,"accession_number":"0001104659-26-106312","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Joseph Truitt as a director and member of the Compensation Committee, effective September 9, 2026. The Board increased its size from six to seven directors specifically to accommodate this appointment. While the disclosure includes compensatory details (initial option grant of 148,000 shares and $40,000 annual retainer), the principal disclosed action is Truitt's appointment to the Board, making this an exec_appointment event. The appointment is material as it affects board composition and governance at a publicly traded biotechnology company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:14:46.287361+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-09-09"},{"id":35495,"accession_number":"0001104659-26-106312","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Joseph Truitt to Century Therapeutics' Board of Directors, announced via press release on September 9, 2026. Truitt brings significant biotechnology leadership experience as CEO of iECURE and Chairman of Larimar Therapeutics, with prior executive roles at BioSpecifics and Achillion. This is a material governance event affecting the composition of the board during a critical period when the company is advancing two key programs toward regulatory milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T20:14:46.287361+00:00","company_name":"Century Therapeutics, Inc.","ticker":"IPSC","filing_date":"2026-09-09"}]}